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Abstract
Introduction Our goal was to specifically render tumor cells
susceptible to natural cytolytic anti-αGal antibodies by using a
murine α1,3galactosyltransferase (mαGalT) transgene driven by
a designed form of HER2/neu promoter (pNeu), the
transcription of which is frequently observed to be above basal
in breast tumors. Indeed, the αGalT activity that promotes
Galα1,3Galβ1,4GlcNAc-R (αGal) epitope expression has been
mutationally disrupted during the course of evolution, starting
from Old World primates, and this has led to the counter-
production of large amounts of cytotoxic anti-αGal antibodies in
recent primates, including man.
Method Expression of the endogenous c-erbB-2 gene was
investigated in various cell lines by northern blotting. A mαGalT
cDNA was constructed into pcDNA3 vector downstream of the
original CMV promoter (pCMV/mαGalT) and various forms of
pNeu were prepared by PCR amplification and inserted in the
pCMV/mαGalT construct upstream of the mαGalT cDNA, in the
place of the CMV promoter. These constructs were transferred
into HEK-293 control and breast tumor cell lines. Stably
transfected cells were analyzed by northern blotting for their
expression of αGalT and c-erbB-2, and by flow cytometry for
their binding with fluorescein isothiocyanate-conjugated
Griffonia simplicifolia/isolectin B4.
Results We show that expression of the mαGalT was up- or
down-modulated according to the level of endogenous pNeu
activity and the particular form of constructed pNeu. Among
several constructs, two particular forms of the promoter,
pNeu250 containing the CCAAT box and the PEA3 motif
adjacent to the TATAA box, and pNeu664, which has three
additional PEA3 motifs upstream of the CCAAT box, were found
to promote differential αGalT expression.
Conclusion Our results strengthen current concepts about the
crucial role played by the proximal PEA3 motif of pNeu, and may
represent a novel therapeutic approach for the development of
targeted transgene expression.
Introduction
The enzyme α1,3galactosyltransferase (αGalT) is responsible
for the synthesis of galactose-α1,3galactose-β1,4N-acetylglu-
cosamine-R (αGal) epitopes in all mammals except Old World
primates [1]. Highly expressed in nonprimate mammals,
prosimians and New World monkeys, this glycosyltransferase
has been mutationally inactivated during the course of evolu-
tion, starting from Old World primates [2]. We have previously
shown that, in human cells, transcription of the αGalT gene is
interrupted by the presence of a strong stop signal in exon 7,
which leads to a chimeric mRNA comprising the first four cod-
ing exons and part of intron VII, but lacking the last two exons
corresponding to the catalytic domain of the enzyme [3]. As a
consequence, and given the broad circulation of αGal carbo-
hydrate antigens, humans, apes and Old World monkeys pro-
duce large amounts of anti-αGal antibodies, which represent
approximately 1% of total IgG in humans [4]. These antibodies
are responsible for the hyperacute rejection of xenografts and
thus prevent trials on transplantation of pig organs to humans
[5,6]. Conversely, they represent a potential constitutive tool
for therapeutic applications because their highly efficient
ad5 = adenovirus type 5; AP-2 = activator protein-2; bp = base pair; FCS = fetal calf serum; FITC-GS-I-B4 = fluorescein isothiocyanate-conjugated 
Griffonia simplicifolia/isolectin B4; αGal = galactose-α1,3galactose-β1,4N-acetylglucosamine-R; αGalT = α1,3galactosyltransferase; GAPDH = 
glyceraldehyde 3-phosphate-dehydrogenase; LTR = long terminal repeat; mαGalT = murine αGalT; NF-kB = nuclear factor kB; pCMV = CMV pro-
moter; PCR = polymerase chain reaction; pNeu = HER2/neu promoter; VSV-G = vesicular stomatitis viral G glycoprotein.
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cytolytic activity could be directed against pathological cells
transgenically modified to express αGal epitopes [7-10].
Gene therapy based on the induction of cytotoxicity generally
makes use of transgenes that encode prodrug activating
enzymes [11]. In the case of anti-αGal-induced cytotoxicity, no
chemical drug is needed to obtain the effect of αGalT because
natural circulating anti-αGal antibodies are sufficient to pro-
mote cell lysis via complement activation. One common prob-
lem with gene therapy is target cell selectivity. A frequent
solution to this is the use of tissue-specific or tumor-activated
promoters to drive expression of the transgene [12,13].
Human c-erbB-2 (synonyms erbB2, HER2/neu), a member of
the erbB family that is overexpressed in about one third of
breast tumors and in a variety of other tumors, is often corre-
lated with a poor prognosis [14-16]. This gene is normally
expressed at a low level in a variety of human embryonic and
adult epithelial and hematopoietic cells [17,18]. The high over-
expression of c-erbB-2 in tumor cells [19] results from multiple
mechanisms, including gene amplification and transcription
modulation [20-22]. c-erbB-2 is a 185 kDa transmembrane
tyrosine kinase receptor related to the epidermal growth factor
receptor that functions as a growth factor receptor to regulate
cell growth and transformation [23-25]. Regulation of the c-
erbB-2 promoter (pNeu) has been extensively investigated in
a domain located within the 700 bp region upstream of its
transcription start site. A -213/-87 fragment relative to the
gene's transcription start site contains the minimal promoter
region able to drive preferential transgene expression in breast
cancer cells [26].
The present study was designed to obtain targeted expression
of αGal epitopes by human breast cancer cells in order to
render them susceptible to anti-αGal antibody-induced cell
death. For this purpose, we used a murine αGalT (mαGalT)
transgene driven by a form of pNeu designed to be signifi-
cantly activated in breast tumor cells.
Materials and methods
Cells and reagents
The cell line HEK-293 (ATCC CRL-1573) and the human
breast cancer cell lines MCF-7 (ATCC HTB-22), SK-BR-3
(ATCC HTB-30), MDA-MB-231 (ATCC HTB-26), and MDA-
MB-453 (ATCC HTB-131) were cultured in Dulbecco's mod-
ified Eagle's medium (Gibco, Invitrogen, Rockeville, MD, USA)
supplemented with 10% fetal calf serum (FCS; BioWhittaker,
Rockland, ME, USA). Fluorescein isothiocyanate-conjugated
Griffonia simplicifolia / isolectin B4 (FITC-GS-I-B4), which
recognizes a terminal galactosyl residue in an α linkage, was
purchased from EY Laboratories (San Matteo, CA, USA). The
rabbit complement ORAX 07 was from Dade Behring (Paris,
France).
Murine αGalT constructions in a plasmid vector and 
transfection
The mαGalT cDNA was kindly provided by Uri Galili and
cloned within HindIII/XbaI sites into pcDNA3 vector (Invitro-
gen, Cergy-Pontoise, France), downstream of the CMV early
promoter (pCMV) or various truncated forms of the HER2/neu
promoter (pNeu) obtained by PCR on genomic DNA extracted
from human CEM cells (ATCC CCL-119) using the following
primer sets: 5'-GGGGGTCCTGGAAGCCACAAG-3' and 5'-
GTGCTCACTGCGGCTCCGGCC-3' for pNeu664 (-488/
+176); 5'-TCGCGAGCAGGCAACCCAGGCGTCCCG-3'
and 5'-AAGCTTCTCCCCTGGTTTCTCCGGTCCCAA-3' for
pNeu250 (-216/+34); 5'-TCGCGAGCAGGCAACCCAG-
GCGTCCCG-3' and 5'-CCAAAAAGCTTGTGCTCACT-
GCGGCTCCGGCC-3' for pNeu392 (-216/+176); 5'-
GGAAATCGCGAAGGAAGTATAAGAATGAAG-3' and 5'-
CCAAAAAGCTTGTGCTCACTGCGGCTCCGGCC-3' for
pNeu209 (-33/+176). All pNeu derivative forms were con-
structed within NruI/HindIII sites upstream of mGalT cDNA in
the place of pCMV.
Cells were transfected in six-well plates using FuGENE 6
transfection reagent (Roche Diagnostics, Meylan, France), as
recommended by the manufacturer. Stably transfected cells
were selected by G418 resistance.
Murine αGalT constructions in a retroviral vector
To overcome the poor efficiency of classic methods of trans-
fection in MDA-MB-231 cells, a retroviral vector system was
developed. The undesirable promoting activity of the 5' long
terminal repeat (LTR) was avoided by constructing the cas-
sette pNeu250/mαGalT in a self-inactivating murine retroviral
vector (pcPM∆U3) that had been prepared by removing nearly
the entire U3 region of the 3' LTR (Lefebvre JC and March D,
manuscript in preparation). Making use of this strategy,
described in [27], the U3 deletion is transferred to the 5' LTR
during the first retrotranscription of the retroviral construct,
and further results in the transcriptional inactivation of the pro-
virus in the infected cells. In addition, the cassette pNeu250/
mαGalT was oriented in the opposite direction (3' to 5') to the
LTR so as to completely rule out any residual viral promoter
activity. To obtain retroviral particles pseudotyped with a vesic-
ular stomatitis viral G glycoprotein (VSV-G), the plasmid con-
struct was co-transfected in GP2-293 packaging cells with a
pVSV-G vector (both from Clontech, BD Biosciences, Le Pont
de Claix, France). Supernatants were harvested 48 h post-
transfection and filtered (membrane pore size = 0.45 µm).
VSV-G pseudotyped particles were concentrated by ultracen-
trifugation. Infected cells were seeded in 24-well plates (BD
Falcon, Le Pont de Claix, France) and stably transduced sub-
clones were selected by antibiotic resistance. Expression of m
αGalT was evaluated using GS-I-B4 reactivity.
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Flow cytometry analysis
Phenotypic analyses were performed using FITC-GS-I-B4, as
previously described [28]. Stained cells were analyzed on a
FACScan cytometer (Becton Dickinson, San Jose, CA, USA).
Northern blot analysis
Total RNAs were isolated using RNA Now reagent (Biogentex
Inc., Seabrook, TX, USA), according to the manufacturer's
instructions, and poly(A)-rich RNAs were selected as
described elsewhere [29]. Poly(A)-rich RNAs (3 µg) were
electrophoresed on denaturing 1.2% agarose gel and trans-
fered in 20 × NaCl/Citrate onto a Hybond-N+ nylon mem-
brane (Amersham-Biosciences, Saclay, France). Membranes
were probed overnight at 42°C with [α-32P]-random-labeled
mαGalT or c-erbB-2 cDNA and washed according to stand-
ard procedures. The mαGalT probe was excised from the
pcDNA3 construct and the c-erbB-2 probe was obtained by
PCR amplification on genomic DNA from SK-BR-3 cells with
the primer set 5'-CCAGGAGGTGCAGGGCTACG-3' and 5'-
ATCCTCAGAACTCTCTCCCC-3'. Membranes were
exposed to Kodak XAR film (Eastman Kodak, Rochester, NY,
USA). Detection of glyceraldehyde 3-phosphate-dehydroge-
nase (GAPDH) was used as an internal control.
Cytotoxicity assay
Parental and transfected HEK-293, MCF-7, or SK-BR-3 cells
were distributed in 96-well plates (5.104 cells/well) and incu-
bated for 1 h after addition of 10 µl of various human sera, in
triplicate. Rabbit complement (20 µl) was then added and
plates were incubated for 1 h. Cell death was evaluated by the
trypan blue vital dye exclusion method. The percentage of
killed cells was evaluated by comparison of the number of
blue-stained cells in the reaction and control wells.
Cell proliferation assay
After cell incubation with human sera and rabbit complement
as above, XTT reagent from the Cell Proliferation Kit II (Roche
Diagnostics, Meylan, France) was added, according to the
manufacturer's instructions, and the cells were re-incubated at
37°C for 2 h. Formazan formation was measured at 490 nm.
Statistical analysis
Statistical comparison of mean values was performed with a
one-way analysis of variance (ANOVA).
Results
Expression of the c-erbB-2 gene in various cell lines
Expression of the endogenous c-erbB-2 gene was investi-
gated in various cell lines by northern blotting. c-erbB-2 was
very weakly expressed in HEK-293 cells and was differentially
transcribed in human breast cancer cell lines (Figs 1 and 2C):
it was absent in MDA-MB-231, moderately expressed in MCF-
7 and MDA-MB-453, and strongly expressed in SK-BR-3
cells. These results are consistent with data published by oth-
ers [21,30,31]. SK-BR-3 cells are known to overexpress c-
erbB-2 as the result of gene amplification in proportions esti-
mated at up to 13:1 [21]. MCF-7 is a known HER2/neu non-
amplified cell line [20], but various degrees of gene expression
have been reported [30,32-34]. The HER2/neu transcription
level of the MCF-7 cell line used in our laboratory was notably
superior to that of the HEK-293 cells (Fig. 1). Serially pas-
saged in different laboratories, MCF-7 cell lines probably
exhibit variable levels of HER2/neu transcription. Immortalized
by adenovirus type 5 (ad5) [35], HEK-293 cells require con-
tinuous ad5 E1A expression to proliferate and avoid senes-
cence [36], and can thus be considered subnormal because
they are not tumorigenic [37]. Interestingly, their very weak
HER2/neu expression done them useful as controls to investi-
gate the activation of various forms of pNeu as a function of
HER2/neu expression in breast tumor cells. Because our goal
was to take advantage of differential up-regulation of endog-
enous pNeu to overexpress a suicide transgene that is itself
driven by an exogenous pNeu, MCF-7 cells without HER2/neu
gene amplification appeared more suitable than HEK-293
cells. SK-BR-3 cells might provide other information, as
detailed hereafter.
Variable activity of mαGalT driven by various forms of c-
erbB-2 promoter in human breast cancer cell lines
Figure 1
Expression of the c-erbB-2 gene in various cell lines  in various cel  lines. Total RNAs from HEK-293 and human breast cancer cell lines MCF-7, SK-BR-3, MDA-MB-231 
and MDA-MB-453 were probed with c-erbB-2 cDNA and thereafter with glyceraldehyde 3-phosphate-dehydrogenase (GAPDH) cDNA as a control.
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Human cells do not express any αGalT activity responsible for
αGal epitope expression that is recognized by the GS-I-B4
lectin. GS-I-B4 binding might thus specifically reveal expres-
sion of exogenous mαGalT in transgenically modified human
cells. A mαGalT cDNA was constructed into pcDNA3 vector
downstream of the original pCMV (pCMV/mαGalT). In addi-
tion, various forms of pNeu were prepared by PCR amplifica-
tion (Fig. 2a): pNeu664 (nucleotides -488/+176, relative to
the transcription start site of HER2/neu), pNeu392 (nucle-
otides -216/+176) and pNeu250 (nucleotides -216/+34).
These forms were inserted in the pCMV/mαGalT construct
upstream of the mαGalT cDNA, in the place of the original
pCMV (pNeu664/mαGalT, pNeu392/mαGalT and pNeu250/
mαGalT). These constructs were transferred into HEK-293
control and breast tumor cell lines. Stably transfected cells
were analyzed by northern blotting for their expression of
αGalT (Fig. 2b) and c-erbB-2 (Fig. 2c), and by flow cytometry
for their binding with FITC-GS-I-B4 (Fig. 3a–c). pCMV and
pNeu664 promoted noticeable expression of αGalT in both
HEK-293 and breast cancer cell lines (Fig. 2b, lanes 2–3, 7–
8 and 12–13). In contrast, the shortest form, pNeu250, raised
αGal expression to a more specific level in MCF-7 than in
HEK-293 cells (Fig. 2b, compare lane 10 to 5). Similar differ-
ential results were observed with pNeu392 (Fig. 2b, compare
lanes 9 and 14 to 4) whereas a complete switch-off was
observed with pNeu209 (data not shown). These results were
verified phenotypically. Elevated αGal expression was
observed in breast tumor and HEK-293 cells with mαGalT
driven by pCMV or pNeu664, while pNeu250 promoted αGal
expression only in the breast tumor cells SK-BR-3 and MCF-7
(Fig. 3a). To confirm these results, expression of the cassette
pNeu250/mαGalT was compared for breast tumor cells
expressing and not expressing c-erbB-2. The non-expressing
MDA-MB-231 cell line, although appropriate for this purpose,
was unfortunately resistant to classic transfection methods. A
self-inactivating retroviral vector pseudotyped by a VSV-G
glycoprotein was thus used to transfer pNeu250/mαGalT.
Stably transduced cell lines were subcloned during the course
of antibiotic selection. Four to five subclones of each type
were analyzed for the expression of mαGalT. The MDA-MB-
231 cells, which did not express c-erbB-2, showed a very low
level of GS-I-B4 reactivity compared to breast tumor cell lines
SK-BR-3 and MCF-7, which express c-erbB-2 (Fig. 3c).
Apparently conflicting results show that pNeu250 promoted
clearly higher αGal expression in MCF-7 than in SK-BR-3 cells
(Fig. 3a,b), while c-erbB-2 was inversely expressed in these
two cell lines (Fig. 1, lanes 2 and 3; Fig. 2c, lanes 4 and 7).
These data could be explained by the differential mechanisms
that sustain HER2/neu overexpression, which is regulated at
the transcriptional level in MCF-7 cells and is dependent on
the existence of multiple gene copies in SK-BR-3 cells. Inter-
estingly, pNeu250 promoted a much more specific expression
as a function of the differential level of endogenous c-erbB-2
transcription in breast tumor cells (Fig. 1, lanes 2–4) and HEK-
293 cells (Fig. 1, lane 1).
Cytolytic activity of anti-αGal antibodies to 
transgenically modified breast tumor cells
A high fraction of antibodies from human sera bind αGal
epitopes and can efficiently induce the death of cells that
exhibit these epitopes via complement activation [4]. Cytotox-
icity assays were carried out on HEK-293, MCF-7 and SK-BR-
3 cells stably transfected by mαGalT cDNA under the control
of pNeu664 and pNeu250, or pCMV used as a control. The
susceptibility of transfected cells to natural human anti-αGal
antibodies was verified using a complement-dependent cyto-
toxicity test (data not shown). Cell death averages were con-
firmed by an XTT proliferation assay (Fig. 4). All of the cell
types transfected with pCMV/mαGalT or pNeu664/mαGalT
were killed, but to varying degrees (Fig. 4). Interestingly, differ-
ential cytolytic activity of antibodies was observed with
pNeu250/mαGalT, being much greater in MCF-7 and SK-BR-
3 cells than in HEK-293 cells (Fig. 4). Here again, mαGalT
was much more efficiently driven by pCMV or pNeu664 in
HEK-293 cells than in breast tumor cells. pNeu250 gave dif-
ferential results that were in favor of the tumor cells; it pro-
moted a more significant proportion of death in MCF-7 than in
SK-BR-3 cells (Fig. 4) that correlated with their respective lev-
els of αGal epitope expression (Fig. 3).
Discussion
Efforts to develop anticancer therapies based on suicide
transgenes generally focus on prodrug activating enzymes
[38] combined with effective targeting of pathological cells.
We have been studying αGalT gene expression and the very
high efficiency of natural anti-αGal antibodies in inducing com-
plement-mediated cell killing [39,40] in the field of hyperacute
xenograft rejection. We attempted to take advantage of this
constitutive immune system to target tumor cells. Several
authors have demonstrated the efficacy of natural anti-αGal
antibodies for destruction of tumor cells [7-10]. Indeed, the
high numbers of circulating oligosaccharides bearing αGal
epitopes are responsible for constant booster immunizations.
This may explain the high plasma level (1% of IgG) of anti-αGal
antibodies in humans [4] and their constant de novo synthesis
in αGalT knockout mice [41,42]. Natural anti- αGal antibodies
are highly cytotoxic and cytolytic as the result of highly efficient
complement activation, and this results in hyperacute rejection
of xenografts [2,40]. They have also been shown capable of
protecting αGalT-deficient mice against engrafted αGal+
colon cancer cells [9].
The purpose of this study was the targeting of tumor cells
known to overexpress c-erbB-2 using a selected form of its
promoter pNeu to drive an active αGalT. This approach was
designed to take advantage of the effective antibodies preex-
isting in all humans. In a similar study, a derived form of the
human telomerase promoter was shown to render human pan-
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creatic carcinoma cells susceptible to αGal/complement-
mediated cell killing [43]. We selected pNeu because it has
been well characterized and is overexpressed in a variety of
tumors [16,44]. Because definition of a precise pNeu
sequence with well-restricted activation in tumor cells remains
uncertain, however, we analyzed several forms of this pro-
moter. The shortest form, pNeu209, which comprises the only
PEA3 motif adjacent to the TATA box plus two SP1 sites and
one AP-2 site downstream of the transcription start site, pro-
moted very weak αGal expression. The minimal forms,
pNeu392 and pNeu250, were equally capable of selectively
inducing αGalT in breast tumor cells compared with HEK-293
cells. We thus concluded that the Ap-2 and SP1 motifs down-
stream of the transcription start site (Fig. 2) were not essential.
The noticeable absence of a CCAAT box in pNeu209 proba-
bly explains its disrupted activity because in cells over-
expressing c-erbB-2, the CCAAT box is up-regulated rather
than the TATAA box [45]. Further studies thus focused on
Figure 2
Promoting activity of newly designed forms of pNeu in various cell lines differentially expressing c-erbB-2 (a) Schematic representation of various forms of pNeu constructed up tream f the murin  α1,3galactosyltran ferase (mαGalT) cDNA
forms of pNeu constructed upstream of the murine α1,3galactosyltransferase (mαGalT) cDNA. The transcription start site is indicated by arrows, 
and the 5' end points of the various forms of pNeu by bold bars. (b) Northern blot analysis of expression of mαGalT driven by the CMV promoter 
(pCMV) and the various forms of constructed pNeu. (c) Northern blot analysis of c-erbB-2 expression in stably transfected HEK-293, MCF-7 and 
SK-BR-3 cells. Total RNAs were electrophoresed and probed with [α-32P]-random-labeled mαGalT or c-erbB-2 cDNA, and thereafter with glyceral-
dehyde 3-phosphate-dehydrogenase (GAPDH) cDNA as a control.
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comparing pNeu250 with the longest form, pNeu664. This
last form contains several PEA3, NF-kB, HER2 transcription
factor (HTF) and SP1 sites upstream of the minimal pNeu250.
The role played by the Ets family and activator protein-2 (AP-
2) factors has been extensively studied in breast tumor cells.
While the AP-2 binding site was present in both pNeu250 and
pNeu664, the main difference between these forms was the
presence of three additional PEA3 motifs in pNeu664. Activa-
tion of pNeu664 was virtually the same in MCF-7 and SK-BR-
3 tumor cells, whereas a marked decrease in pNeu250 activity
was observed only in SK-BR-3 cells (Fig. 3), in complete con-
trast to their high c-erbB-2 expression (Fig. 2c). As discussed
above, the striking overexpression of c-erbB-2 in SK-BR-3
cells can be explained by their multiple gene copies. In MCF-
7 cells, the differential promoting activity of pNeu250 could be
explained by the relative increase in the transcription level
compared with HEK-293 cells. In other aspects, in association
with c-erbB-2 gene amplification, up-regulation of transcrip-
tional factors that control endogenous pNeu remains possible.
Conflicting results have been published on Ets regulation of c-
erbB-2, with activation and repression of pNeu by PEA3 fac-
tors having been reported [46,47]. The observation that Ets
binding leads to a severe bend in DNA could be further sup-
port for our findings [46]. When the number of PEA3 binding
sites is reduced from four in pNeu664 to one in pNeu250,
over-occupation of the single remaining site in pNeu250 might
hinder formation of the required DNA conformation rather than
favor its reading.
The differential promoting activity of pNeu664 and pNeu250
in HEK-293 cells (Fig. 3) does not appear to be relevant to the
transcriptional regulation of c-erbB-2 because this gene is
only weakly expressed in these cells (Fig. 1, lane 1). In
Figure 3
Expression of Galα1,3Gal residues at the surface of transduced cells. 
Cells stably transduced or not with CMV promoter (pCMV)/murine 
α1,3galactosyltransferase (mαGalT), pNeu664/mαGalT, or pNeu250/
mαGalT were labeled with fluorescein isothiocyanate-conjugated Grif-
fonia simplicifolia/isolectin B4 (FITC-GS-I-B4) lectin (Galα1,3Gal) and 
analyzed on a FACScan cytometer (counts, cells numbers; FL1-H, fluo-
rescence intensity). (a) Binding of FITC-GS-I-B4 to parental and 
pNeu250/mαGalT transduced HEK-293, MCF-7 and SK-BR-3 cells. 
Mean values of fluorescence detected by flow cytometry at the surface 
of stably transduced cells with (b) the constructs pNeu664/mαGalT or 
pNeu250/mαGalT in a plasmid vector (experiments in triplicates), and 
(c) the construct pNeu250/mαGalT in a self-inactivating retroviral vec-
tor (experiments were conducted using four to five subclones).
Figure 4
Cytotoxicity assays on HEK-293, MCF-7 and SK-BR-3 cells stably transfected or not with CMV promoter (pCMV)/murine α1,3galactosyltransferase (mαGalT), pNeu664/  αGalT, or pNeu250/mαGalT
transfected or not with CMV promoter (pCMV)/murine 
α1,3galactosyltransferase (mαGalT), pNeu664/m αGalT, or pNeu250/
mαGalT. Cells were distributed in 96-well plates (5.104/well) and incu-
bated with human sera, after which rabbit complement was added. Cell 
death was analyzed using an XTT reagent proliferation assay. Results 
(means of triplicates) are expressed as percentages of cell death, rela-
tive to the amount of formazan formation (absorbance evaluated at 490 
nm; NS, not significant).
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contrast, HEK-293 cells continuously express ad5 E1A, which
has been shown to target pNeu [48] as a repressor of HER2/
neu overexpression [49], and has been proposed for use in
cancer gene therapy [50]. Like the Ets factors expressed in
tumor cells, an equal level of E1A in HEK-293 cells might acti-
vate pNeu664, which contains four PEA3 motifs, and repress
pNeu250, which has only one.
Our efforts to take advantage of natural cytotoxic anti-αGal
antibodies as a means of destroying breast tumor cells, and to
design a promoter specific for these undesirable cells, have to
be considered as a preliminary contribution to the field of can-
cer gene therapy, given that our results have been obtained in
cell line culture models. It has been shown that human primary
breast tumors can be successfully engrafted into NOD/SCID
mice and maintained in a growing state for more than 100
days [51]. Moreover, αGalT(-/-) KO mice have been fortu-
nately generated by others [52,53]. So to progress towards a
gene therapy application, we are developing a two step proce-
dure in mice. First, the distribution and expression of the trans-
gene pNeu250/mαGalT, cloned into the retroviral vector
pcPM∆U3 (see Materials and methods), will be studied in a
human breast cancer xenograft model. Various types of human
breast tumor differentially expressing HER2/neu will be
implanted in NOD/SCID mice, and thereafter the transgene
will be injected by a variety of methods. Second, αGalT-trans-
duced tumor pieces will be transplanted into immunocompro-
mised αGalT KO mice to evaluate the tumor destroying activity
of purified human anti-αGal antibodies.
Conclusion
Our results show that the association pNeu250/mαGalT
could be used to target tumor cells overexpressing c-erbB-2,
and thus expose them to the cytolytic activity of natural anti-
αGal antibodies. Development of a discriminating in vivo sys-
tem capable of targeting tumor cells according to their level of
c-erbB-2 expression could prove beneficial.
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